BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bexmarilimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bexmarilimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05428969-2934@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bexmarilimab: Phase 1/2 readout est. (NCT05428969)
DESCRIPTION:Bexmarilimab\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A St
 udy to Assess Safety\, Tolerability and Preliminary Efficacy of Bexmarilim
 ab in Combination With Standard of Care in Patients With Hematological Mal
 ignancies\nEstimated primary completion: March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bexmarilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05428969
URL:https://assetmemo.bio/drug/bexmarilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672769-2934@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Bexmarilimab: Phase 2 readout est. (NCT07672769)
DESCRIPTION:Bexmarilimab\, phase 2\, Higher-Risk Myelodysplastic Syndromes.
 \nStudy: Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Partic
 ipants With Treatment-naïve Higher-risk Myelodysplastic Syndromes\nEstima
 ted primary completion: November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bexmarilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07672769
URL:https://assetmemo.bio/drug/bexmarilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460986-2934@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Bexmarilimab: Phase 1/2 readout est. (NCT07460986)
DESCRIPTION:Bexmarilimab\, phase 1/2.\nStudy: A Phase Ib/II Study to Evalua
 te Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in 
 Metastatic Soft-tissue Sarcoma.\nEstimated primary completion: July 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bexmarilimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07460986
URL:https://assetmemo.bio/drug/bexmarilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718243-2934@assetmemo.bio
DTSTAMP:20261121T005811Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Bexmarilimab: Phase 1/2 readout est. (NCT07718243)
DESCRIPTION:Bexmarilimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumou
 rs\, Melanoma and NSCLC\nEstimated primary completion: 31 January 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bexmarilimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07718243
URL:https://assetmemo.bio/drug/bexmarilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
